Caffeine/ergotamine

Caffeine/ergotamine (trade name Cafergot) is the proprietary name of a medication consisting of ergotamine tartrate and caffeine.[1] This combination is used for the treatment of headaches, such as migraine headache.

Caffeine/ergotamine
Combination of
Caffeinevasoconstrictor, phosphodiesterase inhibitor
Ergotaminevasoconstrictor, neurotransmitter agonist and antagonist
Clinical data
Trade namesCafergot
Identifiers
CAS Number

Use

Correct timing of use is important. Cafergot is an abortive headache treatment, which prevents the development of the headache, rather than a treatment for an established headache. The medication should be administered at the first sign of headache.

There exist some limitations as to the maximum number of tablets that can be taken per day per week. Different sources of drug information may carry different information, and patients are encouraged to ask their pharmacist or prescriber about such details.

Cafergot is currently available as a generic drug (ergotamine tartrate/caffeine)

Mechanism of action

According to a topic review on UpToDate, "ergotamine and dihydroergotamine (DHE 45) bind to 5HT 1b/d receptors, just as triptans do."[2] This along with binding to other serotonergic and dopaminergic receptors is their presumed mechanism of action in treating migraine.[2][3]

Adverse effects

Because the vasoconstrictive effects of ergotamine and caffeine are not selective for the brain, adverse effects due to systemic vasoconstriction can occur. Cold feet or hands, angina pectoris, myocardial infarction,[4] or dizziness are some examples.

It has also been shown to be associated with mitral valve stenosis. [5]

References
  1. Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ (2002). "Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison". European Neurology. 47 (2): 99–107. doi:10.1159/000047960. PMID 11844898. S2CID 72629130.
  2. "Acute treatment of migraine in adults". UpToDate. Wolters Kluwer. 15 January 2018. Retrieved 27 March 2018.
  3. Fanciullacci M, Granchi G, Sicuteri F (November 1976). "Ergotamine and methysergide as serotonin partial agonists in migraine". Headache. 16 (5): 226–231. doi:10.1111/j.1526-4610.1976.hed1605226.x. PMID 977328. S2CID 45861917.
  4. Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Michael K, Welch A, eds. (2006). The Headaches (3rd ed.). Lippincott Williams and Wilkins. p. 463. ISBN 978-0781754002.
  5. Austin SM, el-Hayek A, Comianos M, Tamulonis DJ (October 1993). "Mitral valve disease associated with long-term ergotamine use". Southern Medical Journal. 86 (10): 1179–1181. doi:10.1097/00007611-199310000-00024. PMID 8211344.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.